A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma

This Phase 1b study is testing a new oral medication called PRJ1-3024 in patients with advanced or metastatic melanoma (a type of skin cancer) whose cancer has progressed after at least one prior treatment. **You may be eligible if...** - You are 18 or older - You have confirmed advanced (cannot be surgically removed) or metastatic melanoma (excluding uveal/eye melanoma) - Your cancer has progressed or come back after at least one prior treatment - You are in good general health (ECOG 0-1) - You have at least one measurable tumor on scans - You have a life expectancy of at least 3 months - You are able to swallow pills **You may NOT be eligible if...** - You have had another cancer - You have significant heart disease - You have active hepatitis B, hepatitis C, or HIV - You received a live vaccine in the past 30 days - You have an active autoimmune condition or are on immunosuppressants - You received a previous HPK1 inhibitor (a specific drug class) - You are on strong CYP3A inhibitor or inducer medications that cannot be stopped Talk to your doctor to see if this trial is right for you.